Paul Jamison, a local pub-goer, expresses concern over the impact of GSK Plc's departure from Stevenage, where it has been the largest employer. The drugmaker is relocating its research headquarters, leaving the town's economy uncertain.
GSK Plc agreed another deal with British biotech Relation Therapeutics Ltd. to use artificial intelligence to speed up drug development.
GSK has announced a $2.5 billion savings initiative aimed at enhancing its drug pipeline as it prepares for an impending patent cliff. The company has not yet disclosed the specifics regarding potential job cuts that may accompany this restructuring effort.
GSK Plc plans annual savings of £1.9 billion ($2.5 billion) by 2029, as the drugmaker invests more in its pipeline to replace revenue from the looming patent expiry of an HIV medicine.
GSK Plc halted development of an experimental drug for chronic cough, saying it was “unlikely to transform patient care.”
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
GSK India first-quarter profit rises on steady vaccine demand
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal
GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
GSK beats second-quarter profit estimates, launches $2.52 billion cost savings drive
GSK to invest £400 million in Britain over 3 years as it ramps up R&D efforts
GSK, Hansoh's cancer drug meets main goal of bone cancer trial
US FDA approves GSK's lung cancer drug
Disappointing Data Prompts GSK to Drop Cough Drug Development
GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
GSK to halt further development of cough drug after missing main goal
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
GSK's targeted cancer therapy shows positive results in late-stage study
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
US FDA approves GSK's oral antibiotic for drug-resistant UTIs